Fulcrum Therapeutics
26 Landsdowne Street
Cambridge
Massachusetts
02139
United States
Tel: 617-651-8851
Website: http://www.fulcrumtx.com/
Email: info@fulcrumtx.com
163 articles with Fulcrum Therapeutics
-
In its full year 2022 financial report, released Thursday, Fulcrum Therapeutics revealed further details regarding the full clinical hold placed on FTX-6058 in February.
-
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - March 10, 2023
3/10/2023
Fulcrum Therapeutics, Inc.® announced that the Company granted non-statutory stock options to new employees.
-
Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for the Fourth Quarter and Full Year 2022
3/9/2023
Fulcrum Therapeutics, Inc. today reported financial results for the fourth quarter and full year 2022 and provided a business update, including on FTX-6058.
-
Fulcrum Therapeutics to Host Fourth Quarter and Full Year 2022 Financial Results Conference Call and Webcast on Thursday, March 9, 2023, at 8:00 a.m. ET
3/6/2023
Fulcrum Therapeutics, Inc. today announced that its fourth quarter and full year 2022 financial results will be released on Thursday, March 9, 2023 before the U.S. financial markets open.
-
The hits kept coming for the sickle cell disease space last week as the FDA placed a full clinical hold on Fulcrum Therapeutics’ Investigational New Drug application FTX-6058.
-
Fulcrum Therapeutics Announces Clinical Hold on FTX-6058 in Sickle Cell Disease
2/24/2023
Fulcrum Therapeutics, Inc.® (Nasdaq: FULC) today announced that on February 23, 2023, the U.S. Food and Drug Administration (FDA) verbally informed the company that it has issued a full clinical hold regarding the Investigational New Drug (IND) application for FTX-6058 for the potential treatment of sickle-cell disease.
-
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - February 10, 2023
2/10/2023
Fulcrum Therapeutics, Inc.®, a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, announced that the Company granted non-statutory stock options to new employees.
-
Fulcrum Therapeutics to Participate at the Upcoming SVB Securities Global Biopharma Conference
2/8/2023
Fulcrum Therapeutics, Inc.® (Nasdaq: FULC) today announced that management will participate in a virtual presentation at the SVB Securities Global Biopharma Conference on Wednesday, February 15, 2023 at 10:00 AM ET.
-
Fulcrum Therapeutics Announces Pricing of Upsized Public Offering of Common Stock - Jan 18, 2023
1/18/2023
Fulcrum Therapeutics, Inc. announced the pricing of an underwritten public offering of 9,615,384 shares of its common stock at a public offering price of $13.00 per share.
-
Fulcrum Therapeutics Announces Proposed Public Offering of Common Stock - Jan 17, 2023
1/17/2023
Fulcrum Therapeutics, Inc.®, a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, announced that it has commenced an underwritten public offering of $100.0 million of shares of its common stock.
-
Fulcrum Therapeutics Provides Business Update and 2023 Outlook
1/4/2023
Fulcrum Therapeutics, Inc.® (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today outlined its recent accomplishments and expected 2023 milestones.
-
Fulcrum Therapeutics Announces CEO Transition - Jan 04, 2023
1/4/2023
Fulcrum Therapeutics, Inc.® announced that Robert J. Gould, Ph.D., former founding chief executive officer of Fulcrum and a current member of the Board of Directors, has been appointed interim chief executive officer, effective January 3, 2023.
-
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - December 05, 2022
12/5/2022
Fulcrum Therapeutics, Inc.®, a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, announced that the Company granted non-statutory stock options to new employees.
-
Fulcrum Therapeutics to Participate at Upcoming 2022 BofA Securities Biotech SMID Cap Conference
12/1/2022
Fulcrum Therapeutics, Inc.® (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today announced that management will participate in a virtual fireside chat at the 2022 BofA Securities Biotech SMID Cap Conference, on Thursday, December 8, 2022 at 9:10 a.m. ET
-
Fulcrum Therapeutics® Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - November 11, 2022
11/11/2022
Fulcrum Therapeutics, Inc. announced that the Company granted non-statutory stock options to new employees as inducement awards outside of the Company’s 2019 Stock Incentive Plan.
-
Fulcrum Therapeutics Announces Recent Business Highlights and Third Quarter 2022 Financial Results
11/8/2022
Fulcrum Therapeutics, Inc.® (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today reported financial results for the third quarter of 2022.
-
Fulcrum Therapeutics Appoints Chief Medical Officer and Chief Scientific Officer
11/7/2022
Fulcrum Therapeutics, Inc.® (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today announced the appointment of Santiago Arroyo, M.D., Ph.D., as Chief Medical Officer, and Jeff W. Jacobs, Ph.D., as Chief Scientific Officer.
-
Fulcrum Therapeutics® to Host Third Quarter 2022 Financial Results Conference Call and Webcast on Tuesday, November 8, 2022 at 8:00 a.m. ET
11/2/2022
Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, announced that its third quarter 2022 financial results will be released on Tuesday, November 8, 2022 before the U.S. financial markets open.
-
Fulcrum Therapeutics® to Participate at Upcoming November 2022 Investor Conferences
11/1/2022
Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, announced that management will participate in the following upcoming investor conferences.
-
World Muscle Society Congress 2022: Genentech, Fulcrum and Sarepta Present Latest Findings
10/12/2022
The World Muscle Society 2022 Congress is ongoing in Halifax, Canada, with numerous companies presenting cutting-edge research in neuromuscular diseases. Here’s a look.